Telix Pharmaceuticals Limited American Depositary Shares (TLX) is a publicly traded Healthcare sector company. As of May 21, 2026, TLX trades at $10.28 with a market cap of $3.48B and a P/E ratio of 0.00. TLX moved +0.93% today. Year to date, TLX is +35.62%; over the trailing twelve months it is -37.32%. Its 52-week range spans $6.28 to $30.36. Analyst consensus is buy with an average price target of $17.00. Rallies surfaces TLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Telix Partners with EDAP and Profound to Integrate PSMA-PET Imaging into HIFU and TULSA: Telix signed letters of intent with EDAP TMS and Profound Medical to integrate its PSMA-PET imaging agents Gozellix® and Illuccix® into robotic HIFU and TULSA image-guided ablative therapies for localized prostate cancer. The collaborations will focus on patient selection, treatment planning, monitoring and evidence generation to optimize personalized workflows.
| Metric | Value |
|---|---|
| Price | $10.28 |
| Market Cap | $3.48B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.04% |
| 52-Week High | $30.36 |
| 52-Week Low | $6.28 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover TLX: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $17.00.